We are live on ! Find out more
SCM

Sarissa Capital Management Portfolio holdings

AUM $158M
1-Year Est. Return 103.7%
This Fund
S&P 500
This Quarter Est. Return
-12.46%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$405M
AUM Growth
-$29.7M
Cap. Flow
+$59.6M
Cap. Flow %
14.72%
Top 10 Hldgs %
92.52%
Holding
18
New
2
Increased
3
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$28.1M
2
PCRX icon
Pacira BioSciences
PCRX
+$23.3M
3
AEGR
Aegerion Pharmaceuticals
AEGR
+$9.23M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$9.13M
5
MDCO
Medicines Co
MDCO
+$7.2M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$17.3M

Sector Composition

Rank Sector Weight
1 Healthcare 84.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABBV icon
1
AbbVie
ABBV
$443B
$86M 21.23%
1,580,000
– –
ARIA
2
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$75M 18.53%
12,850,000
– –
MDCO
3
DELISTED
Medicines Co
MDCO
$59.5M 14.69%
1,567,000
+205,100
+15% +$7.2M
DGX icon
4
Quest Diagnostics
DGX
$25.7B
$35.3M 8.73%
575,000
– –
AEGR
5
DELISTED
Aegerion Pharmaceuticals
AEGR
$34.7M 8.58%
2,555,000
+518,171
+25% +$9.23M
ITCI
6
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$25.6M 6.33%
640,000
+280,000
+78% +$9.13M
MRK icon
7
Merck
MRK
$322B
$19.8M 4.88%
419,200
– –
PCRX icon
8
Pacira BioSciences
PCRX
$1.04B
$15.6M 3.86%
+380,000
New +$23.3M
AMGN icon
9
Amgen
AMGN
$208B
$12.4M 3.07%
90,000
-110,000
-55% -$17.3M
ESPR
10
DELISTED
Esperion Therapeutics
ESPR
$10.6M 2.61%
+448,000
New +$28.1M
SEEL
11
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$9.53M 2.35%
6
– –
RPRX
12
DELISTED
Repros Therapeutics Inc.
RPRX
$8.41M 2.08%
1,132,367
– –
VVUS
13
DELISTED
Vivus Inc
VVUS
$4.22M 1.04%
257,394
– –
KIN
14
DELISTED
Kindred Biosciences, Inc.
KIN
$3.58M 0.88%
689,091
– –
AVEO
15
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$2.8M 0.69%
231,376
– –
ANIP icon
16
ANI Pharmaceuticals
ANIP
$1.8B
$1.23M 0.3%
31,000
– –
GYRE icon
17
Gyre Therapeutics
GYRE
$641M
$419K 0.1%
800
– –
CARM
18
DELISTED
Carisma Therapeutics
CARM
$99K 0.02%
2,060
– –

Similar funds

4A
4D Advisors Redondo Beach, California $158M AUM 92.73% 1-Year Est. Return
DAM
Deepwater Asset Management Minneapolis, Minnesota $158M AUM 23.9% 1-Year Est. Return
PCP
Pantera Capital Partners San Francisco, California $158M AUM 600.89% 1-Year Est. Return
CF
CDC Financial Chicago, Illinois $157M AUM
HEM
Henson-Edgewater Management Avon, Ohio $157M AUM
SF
Seros Financial Tempe, Arizona $157M AUM 16.95% 1-Year Est. Return
AC
AlpenGlobal Capital Tahoe City, California $157M AUM
EP
Elkhorn Partners Omaha, Nebraska $157M AUM 11.91% 1-Year Est. Return

Sarissa Capital Management's Q3 2015 Portfolio in Review

As of Q3 2015, Sarissa Capital Management held 18 positions worth $405M, down 6.8% from $435M the previous quarter. Its ten largest holdings account for 93% of the portfolio.

Sarissa Capital Management deployed $59.6M of net new capital in Q3 2015, opening 2 new positions and adding to 3 existing holdings. Its largest new stake was Esperion Therapeutics: 448,000 shares worth $10.6M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 90% a quarter earlier.

On the sell side, the largest reduction was Amgen, an estimated $17.3M trimmed.

  • Sarissa Capital Management's largest Q3 2015 buy was Esperion Therapeutics: 448,000 shares worth $10.6M.
  • Sarissa Capital Management added most to Aegerion Pharmaceuticals in Q3 2015, an estimated $9.23M increase.
  • Sarissa Capital Management's biggest Q3 2015 reduction was Amgen, cutting an estimated $17.3M.
  • Sarissa Capital Management's ten largest holdings make up 93% of its $405M portfolio in Q3 2015.
  • Sarissa Capital Management opened 2 new positions and closed 0 in Q3 2015.
  • Sarissa Capital Management's portfolio value fell 6.8% quarter-over-quarter to $405M.

Based on Sarissa Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.